1) Medical Diagnostics
Abstract
Investigate medical diagnostics ubiquitous and comprehensive against chemical and biological threats (including NTAs, pharmaceutical-based agents, and toxins) by advancing diagnostic innovations; investigating emerging technologies; ensuring medical diagnostics rapid adaptation to emerging threats; harvesting and synergizing the immense volume of diagnostic data; and aligning medical diagnostics capabilities with the FDA pipeline and larger commercial supply chain. This effort is being separated into three thrust areas starting in FY21: Chemical Diagnostics, Diagnostic Building Blocks, and Emerging Threats.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- f83d79afdbeda7fb9c1fe6cf68406872